Dec 12, 2018 · Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Anavex Life Sciences Corp. (AVXL) using our online tools. Anavex Life Sciences (AVXL) Receives FDA Approval of IND ... ANAVEX®2-73 has already received orphan drug designation from the FDA for the treatment of Rett syndrome. “The acceptance of this IND by the FDA is a significant milestone for ANAVEX®2-73 What have you learned from $AVXL? : wallstreetbets Nov 10, 2015 · After the result, Anavex's lead drug has a ~1.1% chance of making it to market. So my prediction was that the stock had no business being run up in the first place, and there was no conceivable alternative other than it running back down to where it belongs.
Anavex Life Sciences Corp. (AVXL). Today's Latest Price: $2.62 USD. 0.01 (-0.38 %). Updated Apr 3 12:00am. Add AVXL to Watchlist · Sign Up
NanoViricides Has Filed Annual Report, Says Company Has Sufficient Cash To Advance Into Clinical Trials SHELTON, CONNECTICUT -- Friday, September, 29, 2017 -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), reports that it has filed its financial year end annual report (Form 10-K) with the Securities and Exchange Commission (SEC) on Thursday, September 28, 2017 in a timely manner. Anavex Life Sciences Stock Forecast | AVXL Stock Predictions See AVXL stock predictions by 1 financial experts and find out if their Anavex Life Sciences stock forecast (AVXL) is more bullish in comparison to other stocks in the Healthcare sector. Geron - GERN - Stock Price & News | The Motley Fool
Anavex Life Sciences Corp.'s (AVXL) CEO Christopher Missling on Q4 2019 Results - Earnings Call Tran  Seeking Alpha - 16 Dec. Get the all the latest news for all your Stocktwits watchlist symbols in one click! Login with Stocktwits.
HOME - ANAVEX Anavex utilizes precision genetic medicine to treat severe and devastating neurological disorders and is focusing on rare diseases with no available therapy (Rett syndrome) as well as neurodegenerative diseases that are on the rise due to aging populations (Parkinson's Disease and Alzheimer's Disease)